Welcome to our dedicated page for CRXT news (Ticker: CRXT), a resource for investors and traders seeking the latest updates and insights on CRXT stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CRXT's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CRXT's position in the market.
Clarus Therapeutics (CRXT) has entered a licensing agreement with McGill University to develop treatments for mitochondrial diseases related to CoQ10 deficiencies. Clarus will pay $350,000 upfront, with potential milestone payments totaling up to $10.5 million. This collaboration aims to address significant medical needs, as CoQ10 deficiencies can lead to severe organ dysfunctions. McGill’s technology could enhance the effectiveness of CoQ10 uptake, offering hope for innovative therapies in a medical area with limited options for treatment.
Clarus Therapeutics Holdings announced its participation in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 20, 2021, at 2:05 p.m. ET. The virtual presentation will be accessible via the Investors section of its website, with an archived version available for 90 days post-event. Clarus focuses on advancing androgen and metabolic therapies for both men and women, and its first product, JATENZO®, targets unmet medical needs. For further details, visit Clarus Therapeutics’ official website.
The business combination between Clarus Therapeutics and Blue Water Acquisition Corp was completed on September 9, 2021, leading to the formation of Clarus Therapeutics Holdings, Inc. The company will trade on the Nasdaq Global Market under the ticker symbols CRXT and CRXTW starting September 10, 2021. This merger generated gross proceeds of approximately $25.3 million, supporting the commercialization of JATENZO® and the development of new therapies. The management team, including Dr. Robert Dudley, will continue to lead the company post-merger.